Group 1 - The core viewpoint of the article is that Beixin Life (688712) has been listed on the Shanghai Stock Exchange, focusing on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] - Beixin Life is recognized as a national high-tech enterprise dedicated to developing transformative solutions for cardiovascular disease diagnosis and treatment [1] - As of September 30, 2025, the company has no single shareholder holding more than 30% of the shares, indicating a relatively dispersed ownership structure [1] Group 2 - The largest shareholder, Song Liang, directly holds 16.1530% of the company's shares and controls an additional 13.4140% through partnerships, giving him a total voting power of 29.5670% [1] - After the recent issuance, Song Liang's direct shareholding is 13.9450%, with an additional 11.5804% controlled through partnerships, resulting in a total voting power of 25.5254% [1] - The total amount raised from the issuance is 998.64 million yuan, with a net amount of 898.89 million yuan allocated for the construction of an interventional medical device industrialization base, R&D projects, and to supplement working capital [2]
今日上市：北芯生命